Food and Drug Administration

Pulmonary-Allergy Drugs Advisory Committee

January 17, 2002

Slides

FloventŪ DiskusŪ NDA 20-833, Advair DiskusŪ NDA 21-077

Sponsor Presentation

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

FloventŪ DiskusŪ and Advair DiskusŪ, David Wheadon, MD, GlaxoSmithKline  ppt   htm

Food and Drug Administration Presentations

FloventŪ DiskusŪ NDA 20-833,  S004, Charles E Lee, MD, FDA   ppt   htm

Advair™ DiskusŪ (Fluticasone propionate/salmeterol inhalation powder), Lydia I Gilbert-McClain, MD, FDA   ppt   htm

Advair and Flovent Diskus Supplements for the COPD indication:  Summary and Questions, Mary Purucker, MD, PhD, FDA   ppt   htm